Tokio Marine Asset Management Co. Ltd. Has $24.71 Million Holdings in Zoetis Inc. (NYSE:ZTS)

Tokio Marine Asset Management Co. Ltd. increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 0.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 126,469 shares of the company’s stock after purchasing an additional 942 shares during the quarter. Zoetis makes up about 1.1% of Tokio Marine Asset Management Co. Ltd.’s investment portfolio, making the stock its 17th biggest holding. Tokio Marine Asset Management Co. Ltd.’s holdings in Zoetis were worth $24,710,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Metis Global Partners LLC boosted its stake in shares of Zoetis by 4.9% during the 3rd quarter. Metis Global Partners LLC now owns 32,187 shares of the company’s stock worth $6,289,000 after acquiring an additional 1,511 shares during the period. Zions Bancorporation N.A. raised its position in shares of Zoetis by 11.8% in the third quarter. Zions Bancorporation N.A. now owns 21,036 shares of the company’s stock valued at $4,110,000 after buying an additional 2,219 shares in the last quarter. KBC Group NV grew its holdings in shares of Zoetis by 3.9% during the 3rd quarter. KBC Group NV now owns 375,167 shares of the company’s stock worth $73,300,000 after purchasing an additional 14,159 shares in the last quarter. Huntington National Bank boosted its position in shares of Zoetis by 5.8% during the 3rd quarter. Huntington National Bank now owns 249,247 shares of the company’s stock worth $48,698,000 after acquiring an additional 13,757 shares in the last quarter. Finally, Plato Investment Management Ltd lifted its position in shares of Zoetis by 13.2% during the 3rd quarter. Plato Investment Management Ltd now owns 8,088 shares of the company’s stock worth $1,579,000 after buying an additional 943 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock traded down $2.17 during trading on Thursday, reaching $174.87. The company’s stock had a trading volume of 118,595 shares, compared to its average volume of 2,530,994. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $78.90 billion, a P/E ratio of 33.32, a price-to-earnings-growth ratio of 2.67 and a beta of 0.90. The business has a 50 day moving average price of $187.61 and a 200-day moving average price of $180.02.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same period last year, the company earned $1.36 EPS. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be paid a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.99%. Zoetis’s dividend payout ratio (DPR) is presently 32.52%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ZTS shares. JPMorgan Chase & Co. upped their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. BTIG Research lifted their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Stifel Nicolaus increased their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.